Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: Which metabolic syndrome?

BJU International

Volumn 101, Issue 11, 2008, Pages 1335-1336

  Smith, Matthew R ^a,c   O'Malley, A James ^b   Keating, Nancy L ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; GONADORELIN AGONIST; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

BODY FAT; CANCER PATIENT; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASE MARKER; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; ISCHEMIC HEART DISEASE; MALE; METABOLIC SYNDROME X; NOTE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; SIDE EFFECT; SUBCUTANEOUS FAT; SUDDEN DEATH; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; METABOLIC SYNDROME X; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 43049142298     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07707.x     Document Type: Note

References (17)

1. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation for prostate cancer. J Clin Oncol 2006 24 : 4448 56
2. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007 110 : 1493 500
3. Tayek JA, Heber D, Byerley LO, Steiner B, Rajfer J, Swerdloff RS. Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism 1990 39 : 1314 9
4. Smith MR, Finkelstein JS, McGovern FJ et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002 87 : 599 603
5. Berruti A, Dogliotti L, Terrone C et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002 167 : 2361 7
6. Smith MR, Lee H, McGovern FJ et al. Metabolic changes during gonadotropin releasing hormone (GnRH) agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008 Epub ahead of print LM, Urdal P, Bechensteen AG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 1995 154 : 100 4
7. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003 104 : 195 201
8. Smith JC, Bennett S, Evans LM et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001 86 : 4261 7
9. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006 91 : 1305 8
10. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008 31 (Suppl. 1 S55 60
11. Despres JP, Lamarche B, Mauriege P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996 334 : 952 7
12. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation 1998 98 : 398 404
13. Anonymous. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 106 : 3143 421
14. Braga-Basaria M, Dobs AS, Muller DC et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006 24 : 3979 83
15. Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 2008 71 : 318 22
16. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005 28 : 2289 304
17. Ferrannini E. Metabolic syndrome: a solution in search of a problem. J Clin Endocrinol Metab 2007 92 : 396 8